HLB Life Science Co. Ltd Total Assets
HLB Life Science Co. Ltd total assets. Based on the latest financial reports, HLB Life Science Co. Ltd (067630) holds total assets worth ₩450.26 Billion KRW (≈ $305.14 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of HLB Life Science Co. Ltd for the company's overall valuation and market capitalisation.
Total Assets of HLB Life Science Co. Ltd (2012–2024)
Total assets of HLB Life Science Co. Ltd from 2012 to 2024. This chart illustrates how HLB Life Science Co. Ltd's total assets have evolved over time, based on quarterly financial data. See today's stock price for HLB Life Science Co. Ltd for real-time trading data and today's change.
HLB Life Science Co. Ltd - Asset Composition Analysis
HLB Life Science Co. Ltd Total Assets Breakdown (December 2024)
HLB Life Science Co. Ltd total assets breakdown as of December 2024. HLB Life Science Co. Ltd's total assets of ₩450.26 Billion consist of 28.8% current assets and 71.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 9.8% |
| Accounts Receivable | ₩18.12 Billion | 3.4% |
| Inventory | ₩6.10 Billion | 1.1% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩44.78 Billion | 8.3% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how HLB Life Science Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is HLB Life Science Co. Ltd's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HLB Life Science Co. Ltd's current assets represent 28.8% of total assets in 2024, an increase from 0.0% in 2012.
- Cash Position: Cash and equivalents constituted 9.8% of total assets in 2024, up from 1.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 8.3% of total assets.
HLB Life Science Co. Ltd Competitors by Total Assets
Key competitors of HLB Life Science Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GeneBioTech Co. Ltd
KQ:086060
|
Korea | ₩80.28 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩575.39 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩267.18 Billion |
|
Komipharm International Co. Ltd
KQ:041960
|
Korea | ₩133.92 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩125.25 Billion |
|
Aprogen Healthcare & Games Inc
KQ:109960
|
Korea | ₩324.89 Billion |
HLB Life Science Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.93 | 1.83 | 10.15 |
| Quick Ratio | 0.88 | 1.77 | 10.03 |
| Cash Ratio | 0.00 | 0.86 | 0.00 |
| Working Capital | ₩-7.10 Billion | ₩83.91 Billion | ₩163.46 Billion |
HLB Life Science Co. Ltd - Advanced Valuation Insights
This section examines the relationship between HLB Life Science Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.73 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 27.3% |
| Total Assets | ₩539.02 Billion |
| Market Capitalization | $106.34 Million USD |
Valuation Analysis
Below Book Valuation: The market values HLB Life Science Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: HLB Life Science Co. Ltd's assets grew by 27.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for HLB Life Science Co. Ltd (2012–2024)
The table below shows the annual total assets of HLB Life Science Co. Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩539.02 Billion ≈ $365.28 Million |
+27.28% |
| 2023-12-31 | ₩423.50 Billion ≈ $287.00 Million |
+2.84% |
| 2022-12-31 | ₩411.79 Billion ≈ $279.06 Million |
+52.06% |
| 2021-12-31 | ₩270.80 Billion ≈ $183.52 Million |
-17.24% |
| 2020-12-31 | ₩327.20 Billion ≈ $221.74 Million |
-19.20% |
| 2019-12-31 | ₩404.94 Billion ≈ $274.42 Million |
+4.84% |
| 2018-12-31 | ₩386.26 Billion ≈ $261.76 Million |
+290.09% |
| 2017-12-31 | ₩99.02 Billion ≈ $67.10 Million |
+19.76% |
| 2016-12-31 | ₩82.68 Billion ≈ $56.03 Million |
+93.63% |
| 2015-12-31 | ₩42.70 Billion ≈ $28.94 Million |
+27.86% |
| 2014-12-31 | ₩33.39 Billion ≈ $22.63 Million |
-30.75% |
| 2013-12-31 | ₩48.23 Billion ≈ $32.68 Million |
+5.14% |
| 2012-12-31 | ₩45.87 Billion ≈ $31.08 Million |
-- |
About HLB Life Science Co. Ltd
HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendoc… Read more